Bil­lion­aire-backed TCR start­up scores its first mar­quee in­dus­try al­liance

SAN FRAN­CIS­CO — A Bay Area start­up out to cre­ate a next-gen play­er in TCRs has just hit a key mile­stone fol­low­ing its re­cent de­but, ink­ing its first big al­liance with a big-name phar­ma while al­so bring­ing in some added in­sights from clin­i­cal op­er­a­tions that can help shape their work.

Ini­tial­ly ramped up in stealth back in 2017 with ear­ly back­ing from Sean Park­er and the Park­er In­sti­tute for Can­cer Im­munother­a­py, 3T Bio­sciences an­nounced a $40 mil­lion A round a few months ago. Now, CEO Ste­fan Scher­er has forged a part­ner­ship with Boehringer In­gel­heim, a large Ger­man phar­ma that re­mains pri­vate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER